News & Updates

A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

Treatment with pemafibrate in patients with type 2 diabetes mellitus (T2DM) yields more favourable effects on lipid profile, as well renal function, as compared with conventional fibrates, a study has found.

The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.

Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.

Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.